| scholarly article | Q13442814 |
| P50 | author | Marcus D Mazur | Q127116014 |
| P2093 | author name string | Shenandoah Robinson | |
| Robert H. Miller | |||
| P2860 | cites work | Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress | Q24611053 |
| Recent trends in erythropoietin-mediated neuroprotection | Q24649547 | ||
| A new mathematical model for relative quantification in real-time RT-PCR | Q27860781 | ||
| Regulated human erythropoietin receptor expression in mouse brain | Q48558987 | ||
| Arrested oligodendrocyte lineage progression during human cerebral white matter development: dissociation between the timing of progenitor differentiation and myelinogenesis | Q48684211 | ||
| Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. | Q48747468 | ||
| Pretreatment with low doses of erythropoietin ameliorates brain damage in periventricular leukomalacia by targeting late oligodendrocyte progenitors: a rat model | Q48930723 | ||
| The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin | Q48962012 | ||
| Distinctive neuropathologic alterations in the deep layers of the parietal cortex after moderate ischemic-hypoxic injury in the P3 immature rat brain | Q48962363 | ||
| Developmental changes induced by graded prenatal systemic hypoxic-ischemic insults in rats | Q48985335 | ||
| Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). | Q50465111 | ||
| Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats. | Q51722736 | ||
| Long-term prognosis in children with neonatal seizures: a population-based study. | Q51897641 | ||
| Erythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia-ischemia in rats. | Q51991847 | ||
| Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y | Q59055743 | ||
| Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia | Q59264393 | ||
| The economic consequences of preterm birth duringthe first 10 years of life | Q61860210 | ||
| Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury | Q73131921 | ||
| Erythropoietin-mediated preservation of the white matter in rat spinal cord injury | Q79400339 | ||
| The effect of prenatal hypoxia on brain development: short- and long-term consequences demonstrated in rodent models | Q28245123 | ||
| Erythropoietin receptor signalling is required for normal brain development | Q28507560 | ||
| Encephalopathy of prematurity includes neuronal abnormalities | Q30993427 | ||
| Births: final data for 2005. | Q31146787 | ||
| Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice | Q33262324 | ||
| Impaired expression of neuroprotective molecules in the HIF-1alpha pathway following traumatic brain injury in aged mice | Q33657749 | ||
| Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. | Q34075461 | ||
| Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades | Q34086191 | ||
| A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. | Q34488111 | ||
| Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke | Q34673506 | ||
| Neonatal loss of gamma-aminobutyric acid pathway expression after human perinatal brain injury | Q35569033 | ||
| Systemic prenatal insults disrupt telencephalon development: implications for potential interventions | Q35569038 | ||
| Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I | Q36449204 | ||
| TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury | Q36545939 | ||
| Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury | Q37250532 | ||
| Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances | Q37253850 | ||
| Brain protection by erythropoietin: a manifold task. | Q37300838 | ||
| Prolonged exposure to lead lowers the threshold of pentylenetetrazole-induced seizures in rats. | Q39731463 | ||
| Expression patterns of erythropoietin and its receptor in the developing midbrain | Q42456856 | ||
| A potential role for erythropoietin in focal permanent cerebral ischemia in mice. | Q42473313 | ||
| Apoptosis has a prolonged role in the neurodegeneration after hypoxic ischemia in the newborn rat. | Q42495072 | ||
| A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety | Q42664024 | ||
| An approach to using recombinant erythropoietin for neuroprotection in very preterm infants | Q43716045 | ||
| Cortical and subcortical lesions impair skilled walking in the ladder rung walking test: a new task to evaluate fore- and hindlimb stepping, placing, and co-ordination | Q43981348 | ||
| Placental HIFs as markers of cerebral hypoxic distress in fetal mice | Q45229590 | ||
| Erythropoietin improves functional and histological outcome in neonatal stroke | Q46477576 | ||
| Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia | Q46628252 | ||
| Erythropoietin prevents the increase in blood-brain barrier permeability during pentylentetrazol induced seizures | Q46847178 | ||
| Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats | Q47285421 | ||
| Chronic conditions, functional limitations, and special health care needs of school-aged children born with extremely low-birth-weight in the 1990s | Q47374540 | ||
| Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s | Q47386422 | ||
| Permanent focal cerebral ischemia activates erythropoietin receptor in the neonatal rat brain | Q48090557 | ||
| Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation | Q48119740 | ||
| Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury | Q48197546 | ||
| Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats | Q48208417 | ||
| Thalamocortical development of parvalbumin neurons in normal and periventricular leukomalacia brains | Q48223292 | ||
| Coordinated developmental recruitment of latent fast spiking interneurons in layer IV barrel cortex. | Q48247379 | ||
| Safety of high-dose recombinant erythropoietin in a neonatal rat model | Q48250618 | ||
| Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats. | Q48353017 | ||
| Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain | Q48403878 | ||
| The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. | Q48421828 | ||
| Erythropoietin is neuroprotective against NMDA-receptor-mediated excitotoxic brain injury in newborn mice. | Q48426321 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| erythropoietin | Q218706 | ||
| P304 | page(s) | 206-221 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Journal of neurosurgery. Pediatrics | Q26841998 |
| P1476 | title | Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury | |
| P478 | volume | 6 |
| Q49826559 | A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis. |
| Q89173729 | A time for cocktails and inclusion |
| Q55437499 | Alterations of Both Dendrite Morphology and Weaker Electrical Responsiveness in the Cortex of Hip Area Occur Before Rearrangement of the Motor Map in Neonatal White Matter Injury Model. |
| Q36422327 | Cervical spinal erythropoietin induces phrenic motor facilitation via extracellular signal-regulated protein kinase and Akt signaling |
| Q34026944 | Complex pattern of interaction between in utero hypoxia-ischemia and intra-amniotic inflammation disrupts brain development and motor function. |
| Q90056963 | Current Evidence on Cell Death in Preterm Brain Injury in Human and Preclinical Models |
| Q35003575 | Developmental expression of N-methyl-D-aspartate (NMDA) receptor subunits in human white and gray matter: potential mechanism of increased vulnerability in the immature brain |
| Q36520524 | Erythropoietin Modulates Cerebral and Serum Degradation Products from Excess Calpain Activation following Prenatal Hypoxia-Ischemia |
| Q34053756 | Erythropoietin attenuates loss of potassium chloride co-transporters following prenatal brain injury |
| Q37496924 | Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor. |
| Q35909929 | Erythropoietin in brain development and beyond |
| Q37396967 | Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury |
| Q57491952 | Extended Combined Neonatal Treatment With Erythropoietin Plus Melatonin Prevents Posthemorrhagic Hydrocephalus of Prematurity in Rats |
| Q55413545 | Extended Erythropoietin Treatment Prevents Chronic Executive Functional and Microstructural Deficits Following Early Severe Traumatic Brain Injury in Rats. |
| Q27005953 | Growth factors for the treatment of ischemic brain injury (growth factor treatment) |
| Q27345014 | Human Umbilical Cord Blood Cells Ameliorate Motor Deficits in Rabbits in a Cerebral Palsy Model |
| Q64263332 | Ibuprofen Treatment Reduces the Neuroinflammatory Response and Associated Neuronal and White Matter Impairment in the Growth Restricted Newborn |
| Q37724782 | Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury. |
| Q55513191 | Mild Intrauterine Hypoperfusion Leads to Lumbar and Cortical Hyperexcitability, Spasticity, and Muscle Dysfunctions in Rats: Implications for Prematurity. |
| Q45162312 | Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats |
| Q89586204 | Neonatal and Long-Term Consequences of Fetal Growth Restriction |
| Q47216442 | Neonatal erythropoietin mitigates impaired gait, social interaction and diffusion tensor imaging abnormalities in a rat model of prenatal brain injury |
| Q39004400 | Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment |
| Q37347049 | Neonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and current treatment concepts |
| Q60917211 | Neuropathology in intrauterine growth restricted newborn piglets is associated with glial activation and proinflammatory status in the brain |
| Q38188856 | Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates |
| Q35037632 | New antioxidant drugs for neonatal brain injury. |
| Q30405077 | Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia |
| Q37946499 | Organ-protective and immunomodulatory effects of erythropoietin--an update on recent clinical trials |
| Q26852406 | Pharmacologic neuroprotective strategies in neonatal brain injury |
| Q38760911 | Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives |
| Q35956626 | Postnatal Erythropoietin Mitigates Impaired Cerebral Cortical Development Following Subplate Loss from Prenatal Hypoxia-Ischemia |
| Q38365734 | Preclinical Models of Encephalopathy of Prematurity |
| Q36022351 | Prenatal Hypoxia-Ischemia Induces Abnormalities in CA3 Microstructure, Potassium Chloride Co-Transporter 2 Expression and Inhibitory Tone |
| Q39313813 | Prenatal Systemic Hypoxia-Ischemia and Oligodendroglia Loss in Cerebellum. |
| Q34249394 | Prenatal hypoxic-ischemic insult changes the distribution and number of NADPH-diaphorase cells in the cerebellum |
| Q40536441 | Relationship between serum erythropoietin levels and brain injury in preterm infants |
| Q53828021 | Repetitive Neonatal Erythropoietin and Melatonin Combinatorial Treatment Provides Sustained Repair of Functional Deficits in a Rat Model of Cerebral Palsy. |
| Q47112777 | Targeting inflammation to reduce brain injury in growth restricted newborns: A potential treatment? |
| Q61852472 | The fetus at the tipping point: modifying the outcome of fetal asphyxia |
| Q33631208 | The variability of autophagy and cell death susceptibility: Unanswered questions |
| Q57199037 | Therapeutic potential to reduce brain injury in growth restricted newborns |
| Q89879457 | Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future Research |
Search more.